The US Food and Drug Administration granted clearances for various tests for infectious diseases, coagulation disorders, and drug susceptibility.

Bristol-Myers Squibb Company ( NYSE: BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference November 11, 2024 10:00 AM ET Samit Hirawat - EVP, Chief Medical Officer, Global Drug ...

Q3 2024 Earnings Call Transcript October 31, 2024 Bristol-Myers Squibb Company beats earnings expectations. Reported EPS is ...

Eliquis is the leading anticoagulant worldwide ... really intended to give some context to the decision to increase the sample size given the encouraging blended event rates that we're seeing ...

Yes, it is still Open Enrollment and a new modified Medicare Advantage plan has occurred. In September, subscribers for True ...

A new study found that many people on Medicare with low to moderate incomes don't have enough money to pay for a hospital ...

The first 10 drugs covered under Medicare Part D selected for negotiation under the Medicare Drug Price Negotiation Program include: Eliquis (Prevention ... to determine sample population sizes ...

Given the large sample size, it was crucial to determine not just statistical ... The most commonly used DOACs were as follows: rivaroxaban (1160) and apixaban (984). As for other therapies, the most ...